A composite model including visfatin, tissue polypeptide-specific antigen, hyaluronic acid, and hematological variables for the diagnosis of moderate-to-severe fibrosis in nonalcoholic fatty liver disease: a preliminary study.
BACKGROUND
Histopathological risk factors for end-stage liver failure in patients with nonalcoholic fatty liver disease (NAFLD) include nonalcoholic steatohepatitis (NASH) and advanced liver fibrosis. There is a need for noninvasive diagnostic methods for these 2 conditions.


OBJECTIVE
The aim of this study was to investigate new laboratory variables with a predictive potential to detect advanced fibrosis (stages 2 and 3) in NAFLD.


METHODS
The study involved 70 patients with histologically proven NAFLD of varied severity. Additional laboratory variables included zonulin, haptoglobin, visfatin, adiponectin, leptin, tissue polypeptide-specific antigen (TPSA), hyaluronic acid, and interleukin 6.


RESULTS
Patients with NASH (NAFLD activity score of ≥5) had significantly higher HOMA-IR values and serum levels of visfatin, haptoglobin, and zonulin as compared with those without NASH on histological examination. Advanced fibrosis was found in 16 patients (22.9%) and the risk factors associated with its prevalence were age, the ratio of erythrocyte count to red blood cell distribution width, platelet count, and serum levels of visfatin and TPSA. Based on these variables, we constructed a scoring system that differentiated between NAFLD patients with and without advanced fibrosis with a sensitivity of 75% and specificity of 100% (area under the receiver operating characteristic curve, 0.93).


CONCLUSIONS
The scoring system based on the above variables allows to predict advanced fibrosis with high sensitivity and specificity. However, its clinical utility should be verified in further studies involving a larger number of patients.
Alina
A
Chwist
Marek
M
Hartleb
Andrzej
A
Lekstan
Michał
M
Kukla
Krzysztof
K
Gutkowski
Maciej
M
Kajor
D052242:Adiponectin / Q000097:blood; D000328:Adult; D000368:Aged; D002772:Cholera Toxin / Q000097:blood; D005260:Female; D005355:Fibrosis / Q000175:diagnosis*; D006242:Haptoglobins / Q000032:analysis; D006801:Humans; D006820:Hyaluronic Acid / Q000097:blood; D015850:Interleukin-6 / Q000097:blood; D020738:Leptin / Q000097:blood; D008099:Liver / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D054409:Nicotinamide Phosphoribosyltransferase / Q000097:blood; D065626:Non-alcoholic Fatty Liver Disease / Q000175:diagnosis*; D010455:Peptides / Q000097:blood; D010865:Pilot Projects; D011237:Predictive Value of Tests; D011498:Protein Precursors; D012680:Sensitivity and Specificity; D055815:Young Adult
D052242:Adiponectin; D006242:Haptoglobins; D015850:Interleukin-6; D020738:Leptin; D010455:Peptides; D011498:Protein Precursors; C089984:tissue polypeptide specific antigen; C408043:zonulin; D006820:Hyaluronic Acid; D002772:Cholera Toxin; D054409:Nicotinamide Phosphoribosyltransferase